Pfizer-BioNTech vaccine candidate, BNT162b2, was 90% effective in preventing infection during the phase 3 clinical trial, which enrolled 43,538 participants, with 30% in U.S. and 42% abroad
Covid-19 shakes up world's most expensive cities, how four Canadian provinces have protected their people, Italy runs short of ICU staff and other pandemic-related news across the globe
(Reuters) - Pfizer Inc and BioNTech <22UAy.DE> could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.
States and territories are prepared to begin distributing the vaccines within 24 hours of receiving regulatory authorization
Castillo says Pfizer is 'communicating with both sides' during the transition
The success rate of the vaccine developed by U.S. firm Pfizer and Germany's BioNTech is the highest of any candidate in late-stage clinical trials so far, and experts said it was a significant achieve
Pfizer and BioNTech said they plan to submit the data to other regulatory agencies around the world.
Even the front-runners among vaccine companies would take at least a few months to complete Phase-III trials and evaluate the efficacy and safety of individual vaccines
The companies said their vaccine protected people of all ages and ethnicities
UK govt under lens for £17 bn Covid deals, new cases in Russia top 22,000 a day, six-day lockdown in South Australia, and other pandemic-related news across the globe
Federal health officials met with Pfizer representatives on as Brazil seeks to secure vaccine supplies
The Union Health Ministry said that the central government is examining all possibilities to extend cold chain facilities in case Pfizer's Covid-19 vaccine needs to be procured
Last week, Pfizer and BioNTech said their vaccine was more than 90% effective at preventing Covid-19, based on an initial analysis
The Pfizer vaccine (more than 90 per cent effective) must be stored at minus 20 degrees Celsius. Creating cold chains to deliver this to billions is impossible in any reasonable time
Shares of firms in the sectors have outperformed Sensex in November
Limited number of doses would not be enough to meet India's demand, adds Niti Aayog member
Both companies have reported preliminary findings of more than 90% effectiveness - an unexpectedly high rate - raising hope for an end to the pandemic
Pfizer Inc alleged that the drug makers were planning separately to come out with generic versions of its blockbuster multi-billion dollar drug Ibrance (palbociclib) before expiration of its patent
Hungary and Poland block EU stimulus package, Citi says successful vaccines will see dollar plummet, No virus protection for jailed elderly Taxes and other pandemic-related news across the globe